Aftertreated Polymer (e.g., Grafting, Blocking, Etc.) Patents (Class 424/78.17)
-
Publication number: 20110044930Abstract: The invention relates to novel biodegradable materials which are based on modified polyamino acids and which can be used for the vectorisation of active principle(s) (AP). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provide a novel polymer raw material which can be used for the vectorisation of active principles and which can optimally fulfil all required specifications in said area, namely: biocompatibility, biodegradability and the ability to become easily associated with many active principles or to solubilise said principles and to release same in vivo. Said aim is achieved with novel copolyhydroxyalkylglutamines comprising glutamine units and optionally glutamate units and bearing hydrophobic groups containing between 8 and 30 carbon atoms.Type: ApplicationFiled: January 23, 2006Publication date: February 24, 2011Inventors: Rémi Soula, You-Ping Chan
-
Publication number: 20110038828Abstract: A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.Type: ApplicationFiled: October 27, 2010Publication date: February 17, 2011Applicant: REGENTIS BIOMATERIALS LTD.Inventors: DROR SELIKTAR, LIORA ALMANY
-
Publication number: 20110033398Abstract: A process is disclosed for preparing an emulsion composition by forming a mixture of a silanol functional organopolysiloxane, a boron compound, an emulsifier, and then admixing water to the mixture to form an emulsion. The resulting emulsions are useful for providing benefits in personal care applications, particularly hair care compositions.Type: ApplicationFiled: April 13, 2009Publication date: February 10, 2011Inventors: Severine Cauvin, Glenn Gordon, Bethany Johnson, Donald Liles
-
Publication number: 20110027217Abstract: This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.Type: ApplicationFiled: May 26, 2010Publication date: February 3, 2011Applicant: SELECTA BIOSCIENCES, INC.Inventors: CHARLES ZEPP, GRAYSON B. LIPFORD, YUN GAO, LLOYD JOHNSTON, FEN-NI FU FU, MARK J. KEEGAN, SAM BALDWIN
-
Publication number: 20110027350Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.Type: ApplicationFiled: July 26, 2010Publication date: February 3, 2011Applicants: LIPOXEN TECHNOLOGIES LIMITED, BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Sanjay Jain, Gregory Gregoriadis, Archana Dwivedi, Srijit Nath, Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20110020422Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: ApplicationFiled: October 6, 2010Publication date: January 27, 2011Applicant: Nektar TherapeuticsInventors: Michael J. Roberts, Antoni Kozlowski
-
Patent number: 7875677Abstract: This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.Type: GrantFiled: August 18, 2008Date of Patent: January 25, 2011Assignee: The University of British ColumbiaInventors: John K. Jackson, Jason Zastre, Helen M. Burt
-
Patent number: 7875265Abstract: A subject matter of the invention is a cosmetic composition comprising a cosmetically acceptable organic liquid medium, a block polymer and a plasticizer, characterized in that: the block polymer is a film-forming linear ethylenic polymer, the plasticizer is a compound, the nature and the amount of which are such that the composition is capable of forming a film having a hardness of less than or equal to 35 seconds, the hardness of the film being measured using a Persoz pendulum according to Standard NF-T-30-016, and in particular a compound having a solubility parameter ?h ranging from 5.5 to 11 (J/cm3)1/2. Application to making-up and caring for keratinous substances, in particular the skin.Type: GrantFiled: September 26, 2003Date of Patent: January 25, 2011Assignee: L'OrealInventors: Xavier Blin, Véronique Ferrari
-
Publication number: 20110014245Abstract: A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in which a pharmaceutical compound is bound to titanium dioxide having photocatalytic activity through a hydrophilic polymer. The composite is stable in an aqueous solvent and easily administered into a living body, and adverse drug reactions of the pharmaceutical compound can be reduced by administering the composite into the body and irradiating the composite with a light to photoexcite the titanium dioxide to decompose the pharmaceutical compound in a region where the drug efficacy of the pharmaceutical composition is not required.Type: ApplicationFiled: September 24, 2010Publication date: January 20, 2011Applicant: TOTO LTD.Inventors: Shuji SONEZAKI, Koki KANEHIRA, Yumi OGAMI, Toshiaki BANZAI, Yoshinobu KUBOTA
-
Publication number: 20110002997Abstract: Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix in situ on exposure to a visible light source, such as an IPL device. The preparations provide for a more stabilized composition that is contourable during gelation.Type: ApplicationFiled: May 7, 2010Publication date: January 6, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jennifer H. Elisseeff, Alexander Hillel, H. Janice Lee
-
Publication number: 20110002874Abstract: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.Type: ApplicationFiled: July 7, 2010Publication date: January 6, 2011Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Nicholas A. Peppas, James Z. Hilt, Mark E. Byrne
-
Patent number: 7862807Abstract: Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.Type: GrantFiled: July 18, 2003Date of Patent: January 4, 2011Assignee: University of California, San DiegoInventors: Murray Goodman, Churl Min Seong, Guido Harms
-
Publication number: 20100330025Abstract: The invention provides surface treatments that reduce or eliminate marine biofouling of various surfaces. A surface that is to be subjected to a marine environment can be treated with a mPEG-DOPA. The treated surface is thus rendered less susceptible to fouling of the surface.Type: ApplicationFiled: June 3, 2010Publication date: December 30, 2010Applicant: Northwestern UniversityInventors: Phillip B. Messersmith, Andrea R. Statz Sloan, Bruce P. Lee, Jeffrey L. Dalsin, Daniel Sherman, Haeshin Lee
-
Patent number: 7854924Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: March 30, 2004Date of Patent: December 21, 2010Assignee: Relypsa, Inc.Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
-
Publication number: 20100316588Abstract: The invention relates to elastomeric products that are coated with a thin layer of elastomeric polymeric coating containing an antitoxic agent, particularly a demand disinfectant iodinated resin. The antimicrobial coated catheters are prepared by adding the antitoxic agent to a solution of a liquid elastomeric polymer and then coating the surface of the elastomeric through a dipping or spraying procedure. The antimicrobial coatings can be applied to a variety of different elastomeric products including gloves and catheters and are capable of providing a high level of protection against microbes and other contaminants.Type: ApplicationFiled: April 22, 2010Publication date: December 16, 2010Inventors: Pierre J. Messier, David Ohayon
-
Publication number: 20100316589Abstract: The present invention relates to polycarbophil coated crosslinked amine polymers and/or pharmaceutical compositions comprising polycarbophil coated crosslinked amine polymers. The polycarbophil coated crosslinked amine polymers have several therapeutic applications, including, but not limited to, hyperphosphatemia, chronic kidney disease and End-Stage Renal Disease.Type: ApplicationFiled: December 12, 2008Publication date: December 16, 2010Inventors: Hitesh Bhagat, Adnan Salameh
-
Publication number: 20100310497Abstract: A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride. In the formula I and II , R1, A, R2, R3, m and n are as defined in the description.Type: ApplicationFiled: January 13, 2009Publication date: December 9, 2010Inventors: Mitsunori Harada, Iulian Bobe, Takashi Shimizu
-
Publication number: 20100310496Abstract: The present invention relates to an amino acid-modified organopolysiloxane emulsion obtainable by reacting (a) a carboxy-unprotected amino acid, and (b) organopolysiloxane having an epoxy group in the molecule in an aqueous medium in the presence of a surfactant, is incorporated in a cosmetic product. The present invention also relates to the simple and highly efficient production of emulsions of amino acid-modified polysiloxane, as well as the use of the emulsions as beautifying components.Type: ApplicationFiled: December 25, 2008Publication date: December 9, 2010Inventors: Tomohiro Iimura, Shinya Oguri, Masaru Ozaki, Tadashi Okawa, Bethany Johnson, Anne-Marie Vincent, Giada Tonet
-
Publication number: 20100303912Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.Type: ApplicationFiled: May 14, 2010Publication date: December 2, 2010Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
-
Patent number: 7838122Abstract: Compounds exhibiting angiogenic properties incorporating the structure of Formula I: R3—NH—NH—C(?O)—R2—P—R1??(I) wherein P is a water-soluble, biodegradable polymer, R1 is hydrogen, lower alkyl, lower alkoxy or —R2—C(?O)—NH—NH—R3; each R2 is independently —CH2—, —NH— or O; and each R3 is independently hydrogen or a residue of a naturally occurring alpha-L-amino acid or dipeptide thereof. Polymer networks crosslinked with hydrazide compounds are also disclosed, together with implantable medical devices incorporating the compounds and crosslinked polymers, and angiogenesis-promoting treatment methods, including wound-treatment methods.Type: GrantFiled: May 6, 2008Date of Patent: November 23, 2010Assignee: Rutgers, the State University of New JerseyInventors: Joachim B. Kohn, Kristen S. Labazzo, Durgadas Bolikal
-
Patent number: 7829553Abstract: This invention relates to compositions comprising carbon-based diazeniumdiolates attached to hydrophobic polymers that releases nitric oxide (NO). The carbon-based diazeniumdiolated polymers release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated polymers, compositions comprising such polymers, methods of using such compositions, and devices employing such polymer compositions.Type: GrantFiled: January 6, 2005Date of Patent: November 9, 2010Assignee: Amulet Pharmaceuticals, Inc.Inventors: Ernst V. Arnold, Blaine G. Doletski, Robert E. Raulli
-
Patent number: 7829074Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: GrantFiled: October 18, 2001Date of Patent: November 9, 2010Assignee: Nektar TherapeuticsInventors: Michael J. Roberts, Antoni Kozlowski
-
Patent number: 7820158Abstract: Initiator polymers having an initiator group and a ligand group are provided. The initiator polymers are capable of specifically binding to a receptor on a surface. Using a macromer system, the initiator polymers are useful for the formation of a polymeric matrix on the surface of a material. In particular, initiator polymers are provided that have specificity to pancreatic ? cells and can be used to encapsulate cells for transplantation and the treatment of diabetes.Type: GrantFiled: April 10, 2003Date of Patent: October 26, 2010Assignee: SurModics, Inc.Inventors: Stephen J. Chudzik, Dale G. Swan
-
Patent number: 7815922Abstract: Methods for preparing articles having a bioactive surface comprising treating a substrate to form free reactive groups, depositing a monomer onto the treated substrate, and covalently immobilizing a biologically functional molecule onto the deposited monomer. Additional embodiments include methods for the deposition of the monomer onto the treated substrate in a solvent-free environment. Further embodiments include articles having surfaces prepared using the methods described herein. Additional embodiments include articles prepared using the methods described herein.Type: GrantFiled: May 16, 2005Date of Patent: October 19, 2010Assignee: Becton, Dickinson and CompanyInventors: Bryce Chaney, David Montgomery, Ross W. Jacobson
-
Patent number: 7811556Abstract: A copolymer or a pharmacologically acceptable salt thereof is provided, which contains, as constitutional units, (a) one or more structural units of formula (I): wherein m is an integer of from 3 to 100, Alk represents alkyline, and R1 and R2 are the same or different and each represents hydrogen or optionally substituted alkyl, and (b) one or more structural units of formula (II): wherein R3 represents hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, or a group represented by the formula —NR4R5, wherein R4 and R5 are the same or different and each represents hydrogen or optionally substituted alkyl.Type: GrantFiled: September 22, 2005Date of Patent: October 12, 2010Assignee: Sankyo Company, LimitedInventors: Yuji Kasuya, Masashi Honma
-
Publication number: 20100255058Abstract: A composition comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety is disclosed. A medical article comprising the composition in the coating thereof and a method of fabricating the medical article are also disclosed.Type: ApplicationFiled: June 18, 2010Publication date: October 7, 2010Inventor: Syed F.A. Hossainy
-
Publication number: 20100255062Abstract: The present disclosure describes novel carbon-based diazeniumdiolates agents and compounds or salts or prodrugs thereof that release nitric oxide for the treatment of neuropathic gastrointestinal dysfunction. The neuropathic gastrointestinal dysfunction refers to disorders associated with motility, sensation and neuromuscular function that include but are not limited to conditions such as delayed gastric emptying.Type: ApplicationFiled: June 2, 2008Publication date: October 7, 2010Inventors: Aristotle G. Kalivretenos, Robert E. Raulli, Niaz Sahibzada, Richard Gillis, Mark S. Niedringhaus
-
Patent number: 7807780Abstract: Compositions and methods are provided that are useful for the delivery of therapeutic agents, including nucleic acids. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.Type: GrantFiled: July 20, 2001Date of Patent: October 5, 2010Assignee: Revance Therapeutics, Inc.Inventors: Jacob Waugh, Michael Dake
-
Publication number: 20100247668Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: March 29, 2010Publication date: September 30, 2010Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Patent number: 7803899Abstract: Various methods are described for preparing dry water-soluble polymers with reduced organic impurity content by combining water-soluble polymer in water with at least one dry polar solvent to form a mixture that separates into a first layer comprising a majority of the solvent and water and a second layer comprising a majority of the polymer, then separating the layers and drying the second layer to obtain a solid comprising the water-soluble polymer. Further, or solid polymer products having reduced organic impurity levels and/or moisture content are also described.Type: GrantFiled: September 27, 2006Date of Patent: September 28, 2010Assignee: Buckman Laboratories International, Inc.Inventors: Mark L. Zollinger, James Andrew Ward
-
Patent number: 7794699Abstract: An improved synthetic blood substitute which exhibits excellent long-term storage stability at both high and low temperatures is suitable for use in various biomedical and biotechnical applications, including resuscitation of trauma victims that have suffered massive hemorrhaging, and transfusions for human and veterinary surgical procedures. The artificial blood solution comprises an aqueous carrier, and a dendritic polymer that is capable of carrying oxygen dissolved in the aqueous carrier. The dendritic polymer comprises fluorocarbon moieties and hydrophilic moieties.Type: GrantFiled: January 4, 2006Date of Patent: September 14, 2010Assignee: Michigan Molecular InstituteInventors: Steven N. Kaganove, Paul Satoh, Petar R. Dvornic
-
Publication number: 20100226963Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.Type: ApplicationFiled: February 18, 2010Publication date: September 9, 2010Applicant: Eyeon Particle Sciences LLCInventors: Eugene R. Cooper, David M. Kleinman, Andrew Loxley, Mark Mitchnick
-
Publication number: 20100221329Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.Type: ApplicationFiled: December 3, 2009Publication date: September 2, 2010Applicant: SYNERGY PHARMACEUTICALS, INC.Inventors: Kunwar Shailubhai, Stephen Comiskey
-
Patent number: 7780957Abstract: The invention provides block copolymers formed of poly(ethylene glycol) segments and poly(amino acid derivative) segments having side chains of at least one kind of specific amine residue. The invention also provides polyion complexes of such copolymers with polynucleotides and the like. These block copolymers are useful as carriers for in vivo delivery of active substances such as DNA.Type: GrantFiled: May 7, 2004Date of Patent: August 24, 2010Assignee: The University of TokyoInventors: Kazunori Kataoka, Naoki Kanayama, Keiji Itaka, Shigeto Fukushima, Atsushi Harada
-
Patent number: 7781607Abstract: There is provided a production method in which bis(nitrato)platinum complex, optionally in the concurrent presence of dihalo-platinum complex, and poly(ethylene glycol)-block-poly(glutamic acid) are used at specific ratios and reacted. Coordination compound of an anti-tumor platinum complex with a block copolymer having carboxyl groups on its side chains is efficiently produced.Type: GrantFiled: June 8, 2006Date of Patent: August 24, 2010Assignees: Nanocarrier Co., Ltd., The University of TokyoInventors: Katsutoshi Kobayashi, Shoko Nagasaki, Kazunori Kataoka, Chieko Tsuchiya
-
Publication number: 20100203006Abstract: Embodiments of the invention provide an apparatus or process for devolatilization of flowable materials (such as molten polymers with entrained or dissolved solvent or unreacted monomers or comonomers) using a plate heater having heating channels, the design or operation of which heating channels maintains the flowable material above its bubble point pressure during passage through a larger first zone and then induces flashing in, or downstream of, a smaller second zone of the heating channel. The apparatus enables a higher throughput per heating channel while achieving equivalent or better devolatilization, as compared to current devolatilization apparatus.Type: ApplicationFiled: February 11, 2010Publication date: August 12, 2010Applicant: Dow Global Technologies Inc.Inventors: Craig S. Taylor, Ravindra S. Dixit, Robert P. Shirtum
-
Patent number: 7767197Abstract: The present invention provides an immunogen composition and methods for using the same for the development of immunity, and particularly at mucosal sites in a mammal, thereby providing immunity at the site of entry for many major pathogenic organisms and also systemic immunity. The immunogen composition includes an antigen, a biocompatible polymer, and a liquid vehicle, with the biocompatible polymer and liquid vehicle being present in such proportions and interacting in such a way that the immunogen composition exhibits reverse-thermal viscosity behaviour. A delivery vehicle composition including a drug other than an antigen is also provided. Methods are provided for delivering the compositions of the invention to a host.Type: GrantFiled: June 22, 2001Date of Patent: August 3, 2010Assignee: Endo Pharmaceuticals Colorado LLCInventors: Joan P. Blonder, Claire M. Coeshott, Timothy C. Rodell, Wren H. Schauer, Gary J. Rosenthal
-
Publication number: 20100189679Abstract: A cross-linked polyallylamine or an acid addition salt thereof has both high phosphate adsorption capability and low degree of swelling, and a medical use thereof. The cross-linked polyallylamine or an acid addition salt thereof is obtained by copolymerization of allylammonium dihydrogen phosphate with an acid addition salt of N,N?-diallyl-1,3-diaminopropane in an amount of 5 to 25 mol % with respect to the amount of the allylammonium dihydrogen phosphate, the cross-linked polyallylamine or an acid addition salt thereof having a phosphate adsorption capacity of 2.7 to 5.0 mmol/g; and a degree of swelling of 2.0 to 5.0. The cross-linked polyallylamine or an acid addition salt thereof is useful as a therapeutic or prophylactic agent for hyperphosphatemia.Type: ApplicationFiled: July 10, 2008Publication date: July 29, 2010Applicant: TORAY INDUSTRIES, INC.Inventors: Atsushi Inoue, Kazuharu Suyama, Satoshi Minakami, Mitsuko Miyamoto, Shoichi Itaba
-
Patent number: 7754500Abstract: Asymmetrically branched polymers are combined with bioactive agents for a variety of purposes including drug delivery and conjugation to one member of a binding pair for use in an assay.Type: GrantFiled: November 22, 2004Date of Patent: July 13, 2010Assignee: ANP Technologies, Inc.Inventors: Ray Yin, Dujie Qin, Jing Pan
-
Patent number: 7754200Abstract: Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1-C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl.Type: GrantFiled: May 22, 2006Date of Patent: July 13, 2010Assignee: Genzyme CorporationInventors: Thomas H. Jozefiak, Cecilia M. Bastos, Chad C. Huval
-
Publication number: 20100166695Abstract: Designed herein are multivalent heterobifunctional polymers for binding to a biological target exhibiting biological activity and to an effector template which can affect the biological activity of the biological target or detect the presence of the biological target. The polymers comprise a plurality of pre-arranged heterobifunctional ligands connected thereto, and each heterobifunctional ligand comprises a first functionality capable of binding to the biological target, and a second functionality capable of binding to the effector template. The heterobifunctional ligands are pre-arranged on the polymer so as to form a ternary complex between the polymer, the biological target and the effector template. The polymers, methods and compositions described herein provide an approach for the design and production of new therapeutic agents as well as agents useful in a variety of non-therapeutic applications.Type: ApplicationFiled: March 20, 2008Publication date: July 1, 2010Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: David R. Bundle, Pavel kitov
-
Patent number: 7744861Abstract: Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: September 17, 2004Date of Patent: June 29, 2010Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20100158851Abstract: The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material.Type: ApplicationFiled: December 4, 2009Publication date: June 24, 2010Applicant: The Hong Kong University of Science and Technology Technology Transfer CenterInventors: King Lun Yeung, Wai Kin Leung
-
Patent number: 7736635Abstract: Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by means of hydrolytically stable linkages.Type: GrantFiled: December 14, 2004Date of Patent: June 15, 2010Assignee: UCB Pharma S.A.Inventor: Timothy John Norman
-
Publication number: 20100135949Abstract: Antimicrobial compositions and methods are disclosed. The antimicrobial compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. In one aspect the invention relates a UV curable antimicrobial coating comprising a UV curable composition comprising an oligomer, a momoner, and a photoinitiator which are together capable of forming a UV curable polymer composition. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include cetyl pyridium chloride, cetrimide, alexidine, chlorexidine diacetate, benzalkonium chloride, and o-phthalaldehyde.Type: ApplicationFiled: March 4, 2009Publication date: June 3, 2010Applicant: BECTON, DICKINSON AND COMPANYInventor: David Tien-Tung Ou-Yang
-
Publication number: 20100135909Abstract: A metal treatment composition including Tin (II) Chloride and processed montmorillonite clay. The addition of Tin (II) Chloride to the composition provides Tin for forming a ceramic-metal layer on the surfaces of the friction pair. Tin (II) Chloride provides Chlorine ions for forming Chloric films for protecting juvenile surfaces which form in the friction zone. The clay is heated and pulverized to produce a powder comprising both particles having crystalline layer structure and salts and oxides. The layered crystalline structure of the clay contains slip planes that transversely shift when tangential pressure from the friction pair is applied thereby lubricating the friction pair. The salts and oxides contribute to the formation of the ceramic-metal layer.Type: ApplicationFiled: August 16, 2007Publication date: June 3, 2010Inventors: Zheng-Rong Lu, Todd Kaneshiro
-
Patent number: 7718162Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising a functionalized polyethyleneglycol, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient comprising a functionalized polyethyleneglycol.Type: GrantFiled: December 20, 2002Date of Patent: May 18, 2010Assignee: 3M Innovative Properties CompanyInventors: James S. Stefely, Daniel C. Duan
-
Patent number: 7708979Abstract: Thermogelling polymers are described containing poly (n-isopropyl acrylamide). Solutions of this polymer, copolymers or mixtures of the polymer with a second polymer such as poly(ethylene glycol), poly (vinyl pyrrolidone) or poly(vinyl alcohol) are liquids at room temperature and solids at body temperature. Thus, also provided are methods of implanting a hydrogel into a mammal by injecting the solution as a liquid at a temperature below body temperature into a selected site in the mammal at a temperature below body temperature, which then undergoes thermal phase transition to form a solid hydrogel in situ in the body as the implant warms to body temperature. Methods for using these thermal gelling materials in various applications including nucleus pulposus replacement/augmentation, wound care, disk replacement, cartilage replacement, joint replacement, surgical barriers, gastrointestinal devices, cosmetic and reconstructive surgery, and breast enlargement are also provided.Type: GrantFiled: April 30, 2004Date of Patent: May 4, 2010Assignees: Synthes USA, LLC, Drexel UniversityInventors: Anthony M. Lowman, Michele S. Marcolongo, Alastair J. T. Clemow
-
Publication number: 20100098654Abstract: The present invention relates to methods of treatment of neuroblastoma. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.Type: ApplicationFiled: October 15, 2009Publication date: April 22, 2010Inventors: Fabio Pastorino, Mirco Ponzoni
-
Publication number: 20100098653Abstract: The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat diseases or conditions caused by oxidative stress and other free radical mediated conditions. The antioxidant polymers may also be used for the preparation of antioxidant particulate delivery devices of therapeutic agents.Type: ApplicationFiled: February 29, 2008Publication date: April 22, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: John S. Yu, Bong Seop Lee